Basal cell carcinoma (BCC) represents the most commonly diagnosed human cancer among persons of European ancestry with etiology mainly attributed to sun-exposure. In this study we investigated mutations in coding and flanking regions of the PTCH1 and TP53 genes and noncoding alterations in the TERT and DPH3 promoters in 191 BCC tumors. In addition, we measured CpG methylation within the TERT hypermethylated oncological region (THOR) and transcriptions levels of the reverse transcriptase subunit. We observed mutations in PTCH1 in 59% and TP53 in 31% of the tumors. Noncoding mutations in TERT and DPH3 promoters were detected in 59% and 38% of the tumors, respectively. We observed a statistically significant co-occurrence of mutations at the four investigated loci. While PTCH1 mutations tended to associate with decreased patient age at diagnosis; TP53 mutations were associated with light skin color and increased number of nevi; TERT and DPH3 promoter with history of cutaneous neoplasms in BCC patients. TERT promoter mutations but not THOR methylation associated with an increased expression of the reverse transcriptase subunit.
Abstract
Basal cell carcinoma (BCC) represents the most commonly diagnosed human cancer among persons of European ancestry with etiology mainly attributed to sun-exposure. In this study we investigated mutations in coding and flanking regions of the PTCH1 and TP53 genes and noncoding alterations in the TERT and DPH3 promoters in 191 BCC tumors. In addition, we measured CpG methylation within the TERT hypermethylated oncological region (THOR) and transcriptions levels of the reverse transcriptase subunit. We observed mutations in PTCH1 in 59% and TP53 in 31% of the tumors. Noncoding mutations in TERT and DPH3 promoters were detected in 59% and 38% of the tumors, respectively. We observed a statistically significant co-occurrence of mutations at the four investigated loci. While PTCH1 mutations tended to associate with decreased patient age at diagnosis; TP53 mutations were associated with light skin color and increased number of nevi; TERT and DPH3 promoter with history of cutaneous neoplasms in BCC patients. TERT promoter mutations but not THOR methylation associated with an increased expression of the reverse transcriptase subunit.
Our study signifies, in addition to the protein altering mutations in the PTCH1 and TP53 genes, the importance of noncoding mutations in BCC, particularly functional alterations in the TERT promoter.
Introduction,
Basal cell carcinoma (BCC) accounts for about 80 percent of all skin cancers and it is the most commonly diagnosed neoplasm among the Caucasian population [1] [2] [3] . The tumor originates from stem cells within hair follicles or the interfollicular epidermis and infundibulum 4, 5 . Basal cell carcinoma rarely metastasizes; however, due to sheer number of people affected, the disease poses a considerable health hazard as it causes extensive morbidity through local invasion and tissue destruction 6 . The most common genetic alterations in BCC involve the Hedgehog signaling pathway. Germline mutations in the Hedgehog receptor patched 1 (PTCH1) occur in patients with Gorlin syndrome, a Mendelian disease with a high prevalence of BCC 7 .
Aberrant activation of the Hedgehog pathway is common in sporadic BCC either through mutations in the PTCH1 gene, activating mutations in smoothened (SMO) or loss-of-function mutations in suppressor of fused homolog (SUFU) [8] [9] [10] . Ubiquitous hyper-activation of the Hedgehog has led to development of inhibitors targeting G-protein coupled receptor
Smoothened for treatment of advanced BCC 9, 10 . While, the studies based on exome sequencing have confirmed the centrality of PTCH1 mutations in BCC, the variants within smoothened are reportedly causal in resistance to the inhibitors 11 . The role of other frequent genetic variants in either tumor development or resistance to treatment cannot be ruled out. Other prevalent alterations in BCC include loss of function mutations in TP53 12 .
In addition, various reports have suggested frequent occurrence of mutations within the promoter region of the gene encoding telomerase reverse transcriptase (TERT), the catalytic subunit of telomerase 13 . The mutations within the TERT promoter create de novo binding sites for ETS transcription factors that lead to increased transcription through massive epigenetic histone modification 14, 15 . Methylation within TERT hypermethylated oncological region (THOR) also reportedly de-represses the TERT transcription 16 . Besides TERT promoter, other frequent noncoding mutations in BCC include those involving a bidirectional DPH3 promoter 17 .
In this study, we sequenced 191 BCC lesions and corresponding apparently normal skin surrounding tumors from 115 patients for mutations in the PTCH1 and TP53 genes, and the TERT and DPH3 promoters. We also investigated CpG methylation at the TERT promoter between -560 to -774 bp region from the ATG start site that falls in the THOR. We also measured the effect of the TERT promoter mutations and THOR methylation on the transcription of the catalytic subunit of the telomerase. In addition, we also investigated the correlation between TERT promoter mutations and telomere length.
RESULTS

PTCH1 mutations
We detected 137 PTCH1 mutations in 105 tumors; of those 44 tumors also showed loss of heterozygosity as detected by MLPA including focal deletions on one allele in 4 tumors (Table 1; Supplementary Figure 1 ; Supplementary Table 1 and 2). In addition 7 tumors showed only loss of heterozygosity without a mutation on the remaining allele. One mutation each was detected in 79 (41%) tumors, 21 (11%) tumors carried two mutations each, four tumors had three mutations each and one tumor had four mutations.
The C>T base change was the most frequent mutation with 64 transitions detected in 56 (29%) tumors, followed by CC>TT tandem mutations, and C>A mutations in 8 tumors each.
Thirty-six mutations were missense, 33 were nonsense and 17 mutations were intronic (Figure 1 ). We also detected 37 insertion-deletions (indels) that included 25 frame-shift alterations, 6 in-frame deletions, two truncations, and three intronic. Out of three duplications, two were frame-shift and one in-frame. We also detected 14 mutations at 5' splice sites and 7 mutations at 3' splice sites ( Supplementary Table 3 ). Mutations were distributed throughout the gene from exon 3 to exon 23; exon 23 with 12 mutations had the highest number of alterations followed by exons 18 and 6 with 10 mutations each. Most of the missense mutations were in exon 23 while exon 18 had the largest number of nonsense mutations and indels were most frequent in exon 20.
TP53 mutations
Sixty of the 191 (31%) BCC carried alterations in TP53, with 31 (16%) tumors carrying more than one mutation; 24 tumors carried two mutations and 4 tumors carried three mutations and 3 tumors carried four mutations. In total, 100 alterations in the TP53 gene were identified. The most frequent mutations were C>T transitions with 66 transitions in 48 (25%) tumors, followed by 17 CC>TT tandem transitions in 16 (8%) tumors ( Table 1; Supplementary Table 1 ; Supplementary Table 4 ).
The majority of TP53 mutations were missense, 71 mutations in 51 tumors (37%) and 23 nonsense mutations were present in 20 tumors (4%). The mutations were distributed within the DNA binding domain of TP53 (Figure 1) . The most common missense variant p.P177L (c.530 C>T) in exon 5 was detected in 8 tumors (4%) followed by the p.H179Y (c.535 C>T) mutation in exon 5 in 4 tumors. The truncating mutations detected with the highest frequency were the p.R213* in exon 6 (c.637 C>T) identified in 8 (4%) tumors and p.R196* in exon 6 (c.586 C>T) in 4 (2%) tumors.
TERT promoter mutations
TERT promoter mutations were present in 113 of 191 (59.2%) lesions with the -146C>T mutation in 67 (35.1%) tumors followed by -124C>T in 14 (7.3%) tumors ( Table 1 ; Supplementary Table 1 ). CC>TT tandem mutations at -138_139, -124_125 and -101_102 bp positions were present in 16 (8.4%) tumors. Eight BCC tumors in addition to the -146C>T hotspot mutation also carried additional alterations and in five tumors other than the recurrent hotspot mutations were detected ( Table 1) .
TERT promoter methylation
Pairwise alignment of bisulfite and target genomic sequence using QUMA showed > 85% of homology in 157 (86%) of 183 tumors. Of those 157 tumors, 93 (59%) carried TERT promoter mutations while the remaining 64 (41%) were wild type. The methylation at the screened 14
CpG sites was statistically significantly higher in tumors without the TERT promoter mutations (99%; 870 of 882 methylation sites) than in the tumors with those mutations (96%; 1219 of 1267 methylation sites; Fisher's exact P: 0.0006, Mann-Whitney U-test P: 0.003). The standard errors (SE 0.65 vs 0.78%) between the two groups were not statistically significantly different (F test P: 0.12). Comparison of methylation at individual CpG sites showed a statistically significant differences at positions chr5:1,295,731, hg 19 (97% in tumors without mutations vs 80% in tumors with mutations; Fisher's exact P: 0.003) and chr5:1,295,759 (98% in tumors without mutations vs 90% in tumors with mutations; Fisher's exact P: 0.05).
Analysis of bisulfite converted DNA after cloning also showed statistically significantly higher methylation in tumors without mutations than in those with mutations (Fisher's exact P:
<0.00001, Mann-Whitney U-test P: <0.00001; Supplementary Figure 2 ). Pairwise sequence alignment of cloned bisulfite sequence and the target genomic sequence using QUMA showed more than 95% homology for each clone. Individually at the each CpG sites, tumors without the TERT promoter mutations had statistically significantly higher methylation than the tumors with mutations. The methylation across all 14 CpG sites ranged between 85% -98% in tumors without mutations compared to 44% -91% in tumors with mutations.
DPH3 promoter mutations
Mutations in the DPH3 promoter were present in 73 of 191 (38.2%) tumors. In addition to the frequent C>T transitions observed in 35 (18.3%) tumors at -8 bp and in 14 (7.3%) tumors at -9 bp, CC>TT tandem mutations at -8_9 bp were present in 17 tumors (8.9%). Additional mutations included two C > T transitions at -12 bp, and two C > A transversions at -9 bp. The C>T mutation at -12 bp in two BCCs co-occurred with -8C > T and -8/-9CC > TT mutations, respectively, and the C>T mutation at -13 bp in one BCC co-occurred with -8/-9 CC>TT ( Table   1 ; Supplementary Table 1 ).
Association of mutations with patient and tumor characteristics
Overall, 28 (14.7%) tumors carried alterations at all four loci; 37 (19.4%) tumors carried alterations at three loci (PTCH1 and TERT promoter along with alteration at either TP53 or DPH3 promoter); 32 tumors (16.8%) had alterations in 2 genes (PTCH1 gene and TP53 or TERT promoter or DPH3 promoter); 14 (7.3%) tumors had only PTCH1 mutations, while 42 (22.0%) tumors that were wild type for PTCH1 and carried any of the other alterations ( Figure 1 ). PTCH1 mutations tend to co-occur with: TP53 mutations (OR 7.69; 95% CI 3.38-17.46; P<0.0001), TERT promoter mutations (OR 3.84; 95% CI 2.08-7.07; P<0.0001) and DPH3 promoter alterations (OR 5.09; 95% CI 2.56-10.12; P<0.0001) (Figure 1) . 
TERT expression
RNA was available from 77 BCC tumors and corresponding tumor-surrounding skin. Of 77 tumors, 48 carried TERT promoter mutations, 34 with -146C>T, 8 with -124C>T, 6 with -138_139CC>TT and 29 were without mutations. Data analysis showed statistically significantly higher mRNA levels in BCC tumors with TERT promoter mutations than in tumors without mutations (P < 0.001, t-test; Figure 3 ). Further stratification showed that tumors with TERT promoter mutations and complete methylation (n = 23) had statistically significantly (P = 0.003) higher TERT expression than the tumors with complete methylation and without TERT promoter mutations (n = 14) (Supplementary Figure 3) . Similarly, the tumors with partial methylation and TERT promoter mutations (n = 25) had statistically significantly (P = 0.004) higher TERT expression than corresponding tumors with partial methylation and without the TERT promoter mutations (n = 2). The difference in TERT expression in tumors based on only methylation status was not statistically significant (P = 0.82).
Telomere length
Results from measurement of relative telomere length were available for 174 BCCs and 104 tumor-surrounding skin tissues. Of the 174 BCCs, 100 were with and 74 were without TERT promoter mutations. Relative telomere length ranged between 0.19 and 3.62 with median values of 1.02 in tumor-surrounding skin, 0.81 in TERT promoter wild type BCCs and 0.72 in BCCs with TERT promoter mutations. Tumors had shorter telomeres than surrounding skin; however, a difference in telomere length in BCCs with and without the TERT promoter was not statistically significant (Supplementary Figure 4) .
Discussion
We confirmed the presence of PTCH1 and TP53 mutations in BCC tumors, and showed frequent noncoding mutations within the TERT and DPH3 promoters. TERT promoter mutations, the most frequent alterations, were associated with increased expression of telomerase reverse transcriptase subunit. The increase in TERT expression was due to the mutations and not due to hypermethylation of the oncological region within the TERT promoter.
PTCH1 is a human homolog of the Drosophila segment polarity genes and its inactivation confers Sonic Hedgehog independent growth, genomic instability and tumor development potential. Hedgehog ligands bind to PTCH1, causing internalization and degradation leading to release of smoothened that in turn cascades the transcription of Hedgehog pathway genes in a feedback loop mechanism 18 . Inactivating alterations in PTCH1, consisting of 23 exons, were present in about 59 percent of tumors. In accordance with a central role of UV radiation in the pathogenesis of BCC, the majority of point mutations were represented by C>T and CC>TT transitions as also reported in previous studies 8, 19, 20 . The observed frequency of the PTCH1 mutations in this study was similar to reported in earlier studies albeit lower than that reported in an exome sequencing based genomic analysis 8, 12 .
The TP53 genes encodes p53 transcription factor, a tumor suppressor involved in cellular stress responses including DNA damage, oxidative stress, oncogenic hyperproliferation, pathogenic stimuli, UV-induced pigmentation 21, 22 . Approximately 31% of tumors carried mutations in the gene and a majority of mutations reflected UV signatures. Most of the base changes were predominantly protein altering missense changes and to lesser extent nonsense mutations. The mutations mainly affected the DNA binding domain with typical hotspot mutations as reported earlier in a study based on exome sequencing 12 . The selection for missense mutations in DNA binding domain the gene is driven through dominant negative effect where mutant forms hinder functioning of the protein from intact alleles 23 .
The observed frequency of the mutations in our study was closer to that reported in nonaggressive than in aggressive BCCs 24, 25 . However, in a study based on exome sequencing on a large series of BCC tumors, the frequency of mutations in TP53 was reported to be 61% 8 . We also observed a strong association between TP53 mutations and fair skin; impaired p53 in mice has been shown to result in lack of tanning response and addiction to sunlight 21, 26 .
While the role of mutations in the tumor suppressors PTCH1 and TP53 is well established in BCC pathogenesis, the relevance of noncoding mutations is not well defined. Originally discovered in melanoma, the TERT promoter mutations lead to creation of de novo sites for ETS transcription factors and with a few exceptions are frequent in cancers that arise from tissues with a low rate of self-renewal 13, 14, 27 . The TERT promoter mutations affect the process of tumorigenesis through rejuvenation of telomerase through an increased TERT transcription 13, 14 . Like in melanoma, TERT promoter mutations in BCC tumors are highly prevalent 28, 29 . We observed that TERT promoter with mutations in 59% of tumors in consistent with earlier reports was the most frequently altered loci 28, 29 . Of the two main TERT promoter mutations, -124 C>T and -146 C>T, the former, with the exception of skin neoplasms, is overwhelmingly predominant in most cancers 13 . However, in melanoma and keratinocyte cancers, the -146 C>T is the most frequent TERT promoter mutation as in this study. Skin cancers are also characterized by the presence of CC>TT tandem mutations at -124/-125 and -138/-139 bp positions that lead to similar CCGGAA consensus binding site for ETS transcription factors 30 . The pattern of TERT promoter mutations in skin cancers is indicative of an UV etiology in the genesis of those alterations. The -138/-139 CC>TT tandem mutation in melanoma was shown to be associated with the worst melanoma-specific patient survival 31 . The altered site due to the -146 C>T mutation specifically involves noncanonical NF-kB signaling with cooperative binding between p52/RelB and ETS1 32, 33 . In general sites created by TERT promoter mutations involve binding by multimeric GABPA/GABPB1 complex at ETS transcription factor leading to an epigenetic switch from inactive to active histone mark and pol II recruitment 15 . As reported in previous studies, we detected increased transcription of the reverse transcriptase subunit in BCC tumors with than without the TERT promoter mutations 34, 35 .
We also investigated THOR region where methylation of CpG sites is generally associated with increased TERT expression 16, 36 . However, our data show that increased TERT expression in BCC tumors can be primarily attributed to the promoter mutations as shown in adult gliomas 37 . Telomeres in tumors with the TERT promoter mutations are usually shorter than in tumors without those mutations as observed in melanoma and gliomas 35, 38 . However, we did not observe a statistically significant difference in telomere length in BCC tumors.
Noncoding mutations within the DPH3 promoter were detected in 38% of the lesions. The effect of the mutations, located within the proximity to an Ets binding motif, has been rather ambiguous 17 . The presence of mutations exclusively at dipyrimidinic sites coupled with typical CC>TT tandem alterations in the DPH3 promoter mutations was indicative of an UV etiology. In the absence of a definitively ascribed functionality, the DPH3 promoter mutations as being mere passenger events cannot be ruled out 39 . However, we observed that both TERT promoter and DPH3 mutations associated with an increased risk of cutaneous neoplasms. DPH3 encodes a short peptide involved in electron transfer during the synthesis of eukaryotic diphthamide and forms a complex with Kti13, which is involved in both tRNA and translational elongation factor 2 (EF2) modifications 40, 41 . Overexpression of DPH3 has been shown to promote migratory ability of murine melanoma and downregulation of its expression was shown to inhibit cellular invasion and metastasis in vivo 42, 43 .
In conclusion, we found noncoding mutations within the TERT and DPH3 promoter at high frequency in BCC tumors in addition to frequent alterations in PTCH1 and TP53 genes that impair protein functions. Interestingly, the alterations in PTCH1, TP53 and DPH3 promoter occurred more frequently in tumors with TERT promoter mutations. It is likely that the increased cellular proliferation following the activation of Hedgehog signaling or elimination of checkpoints due to p53 loss would require telomere buttressing due to increased cellular proliferation, which is probably attained through telomerase rejuvenation via TERT promoter mutations.
Material and Methods
Patients and tissues
Fresh-frozen tissues from BCC tumors from 191 patients and apparently normal appearing skin surrounding tumor tissues from 115 patients were included in this study. Seventy-one Table 1 ). During surgical excision of the lesions, a 4 mm intra-tumoral punch biopsy specimen was obtained, snap-frozen in liquid nitrogen and kept at -80°C until nucleic acid extraction. The remaining tissue was formalin-fixed and paraffin-embedded (FFPE) for conventional histopathology.
Mutational Analysis by Sanger Sequencing
DNA and total RNA were extracted from fresh-frozen tissues using the QIAGEN AllPrep DNA/RNA/miRNA Universal Kit (QIAGEN, Hilden, Germany) according to the manufacturer's instruction. Mutations at different loci were screened using PCR and Sanger sequencing using primers and standard conditions ( Supplementary Table 6 ). Sequencing data were analyzed using Geneious Pro 5.6.5 software and sequences from the NCBI gene database were used as references, PTCH1 (chr9: 98,205,262-98,279,339 hg 19 coordinates), TP53
(chr17: 7,565,097-7,590,856 hg19 coordinates), TERT promoter (chr5: 1,295,071-1,295,521, hg 19 coordinates), and DPH3 promoter (chr3: 16, 306, 306 ,755, hg19 coordinates),.
The point mutations in the PTCH1 and TP53 genes were annotated by using web-based tool Mutalyzer 44 . The sequence topology for the PTCH1 gene was generated with PROTTER 45 .
Mutations with intron/exon boundaries were analyzed for the effect on splicing using maximum entropy model 46 . For splice site analysis on the 5' end, three nucleotides from exon and 6 nucleotides from the following intron were included in the model; for 3' splice site, 20 nucleotides from the intron and three nucleotides from the preceding exon were included in the model.
Multiplex ligation-dependent probe amplification (MLPA)
MLPA method with specific probes was used (SALSA MLPA P067-B2 PTCH1 probemix, MRC-Holland, Amsterdam, The Netherlands) to detect deletions/duplications in the PTCH1 gene.
The results were cross-validated by Sanger sequencing and concordant results were confirmed by both methods.
Measurement of TERT promoter methylation
A 213 bp genomic region within the TERT promoter, from -560 to -774 (chr5:1,295,665-1,295,878; hg19) from ATG start site was screened for CpG sites in-silico using MethPrimer 47 .
The selected region included 14 CpG sites and primers were designed to amplify both methylated and unmethylated sequence. PCR product was either sequenced directly or after cloning into T-overhang vector. The sequence data files were further analyzed for CpG methylation status using a web-based bisulfite sequencing analysis tool called QUMA (QUantification tool for Methylation Analysis) under default settings 48 .
Measurement of TERT mRNA expression by quantitative real-time PCR (qRT-PCR)
For measurement of gene expression, reverse transcription reaction was performed using approximately 1.0 µg RNA and random hexamer primers using a cDNA synthesis kit (Thermo Scientific, Waltham, USA). The real-time PCR was carried out in triplicates on a 384-well layout using primers specific for TERT ( Supplementary Table 6 ) and primers for the GUSB gene (Qiagen). Difference in gene expression levels were calculated following the ΔΔC T method; GUSB expression was used as an internal reference (ΔC T ) and difference in expression levels was calculated between BCCs and matched tumor-surrounding skin (ΔΔC T ) followed by performing a log 2 transformation.
Measurement of telomere length
Relative telomere length in tumor DNA was measured using the monochrome multiplex PCR assay as described previously including minor modifications 49, 50 . The standard curve was used to quantify the telomere (T) and albumin genes (S) based on the respective average Ct values obtained in triplicate. The relative telomere length was expressed as the ratio between T/S. Inter-assay and intra-assay variation were determined by duplicating the reference DNA for all the dilutions in all the assays performed.
Statistics
The associations between mutations in PTCH1, TP53, TERT promoter, DPH3 promoter and patient age at diagnosis, sex, phototype, nevus count, solar lentigos, history of cutaneous neoplasms, exposure to sun, immunosuppressive treatment and histology were determined by χ 2 -tests and size of the effect determined by odds ratio (OR) and 95% confidence intervals (CIs) in logistic regression model. Multivariate logistic regression was also carried and included statistically significant variables from univariate analysis. Box plots were drawn to for TERT expression and telomere length in tumors with and without TERT promoter mutations and differences analyzed by two-tailed t-test. Experiments were carried out in triplicates and box plot represent mean ± S.E. P-value was determined by t-test.
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